Implantable infusion pump sales will rise through 2036, driven by patient-controlled analgesia pumps at 28.1% of the product type segment in 2026, supported by established clinical adoption and treatment protocol integration. The market was valued at USD 572.90 million in 2025 and is expected to be worth USD 1,054.15 million by 2036.